GSK Upbeat On Alli In EU As Global Consumer Sales Show Healthy Gains
This article was originally published in The Tan Sheet
Executive Summary
Alli is off to the races in Europe, where it is generating high sales since launching in April, GlaxoSmithKline says
You may also be interested in...
Glaxo Adds Alli Warning Label In Europe
The European Union health authority recommended GlaxoSmithKline add a warning to alli nonprescription weight-loss drug, advising patients taking levothyroxine or antiepileptic drugs, or those with kidney disease, to consult a doctor before using
Glaxo Consumer Finds Growth Groove Via Innovation, Acquisitions, Expansion
GlaxoSmithKline's consumer health care business appears back on track with 8 percent growth in the firm's latest earnings period, a year after it reported flat consumer sales hurt by the disappointing U.S. performance of weight-loss drug alli
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales